Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TGF-beta antagonists: why suppress a tumor suppressor?

× No keyword cloud information.

19 in total

Review 1. TGF-beta signaling: positive and negative effects on tumorigenesis.

Authors: Lalage M Wakefield; Anita B Roberts
Journal: Curr Opin Genet Dev Date: 2002-02 Impact factor: 5.578

Review 2. TGF-beta signaling in cancer--a double-edged sword.

Authors: R J Akhurst; R Derynck
Journal: Trends Cell Biol Date: 2001-11 Impact factor: 20.808

3. Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma.

Authors: K Y Kim; S Y Jeong; J Won; P D Ryu; M J Nam
Journal: J Biol Chem Date: 2001-07-16 Impact factor: 5.157

Review 4. The ErbB receptor family: a therapeutic target for cancer.

Authors: Johann S de Bono; Eric K Rowinsky
Journal: Trends Mol Med Date: 2002 Impact factor: 11.951

5. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis.

Authors: S J Engle; J B Hoying; G P Boivin; I Ormsby; P S Gartside; T Doetschman
Journal: Cancer Res Date: 1999-07-15 Impact factor: 12.701

6. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.

Authors: Sanna-Maria Kakonen; Katri S Selander; John M Chirgwin; Juan Juan Yin; Suzanne Burns; Wayne A Rankin; Barry G Grubbs; Mark Dallas; Yong Cui; Theresa A Guise
Journal: J Biol Chem Date: 2002-04-18 Impact factor: 5.157

7. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.

Authors: A Bandyopadhyay; Y Zhu; M L Cibull; L Bao; C Chen; L Sun
Journal: Cancer Res Date: 1999-10-01 Impact factor: 12.701

8. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.

Authors: Yu-An Yang; Oksana Dukhanina; Binwu Tang; Mizuko Mamura; John J Letterio; Jennifer MacGregor; Sejal C Patel; Shahram Khozin; Zi-Yao Liu; Jeffrey Green; Miriam R Anver; Glenn Merlino; Lalage M Wakefield
Journal: J Clin Invest Date: 2002-06 Impact factor: 14.808

9. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

Authors: Rebecca S Muraoka; Nancy Dumont; Christoph A Ritter; Teresa C Dugger; Dana M Brantley; Jin Chen; Evangeline Easterly; L Renee Roebuck; Sarah Ryan; Philip J Gotwals; Victor Koteliansky; Carlos L Arteaga
Journal: J Clin Invest Date: 2002-06 Impact factor: 14.808

10. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.

Authors: Elzbieta Janda; Kerstin Lehmann; Iris Killisch; Martin Jechlinger; Michaela Herzig; Julian Downward; Hartmut Beug; Stefan Grünert
Journal: J Cell Biol Date: 2002-01-14 Impact factor: 10.539

45 in total

Review 1. Son of a mother against decapentaplegic.

Authors: F C Luft
Journal: J Mol Med (Berl) Date: 2003-01 Impact factor: 4.599

Review 2. Involvement of members of the cadherin superfamily in cancer.

Authors: Geert Berx; Frans van Roy
Journal: Cold Spring Harb Perspect Biol Date: 2009-09-23 Impact factor: 10.005

Review 3. TGFβ biology in cancer progression and immunotherapy.

Authors: Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal: Nat Rev Clin Oncol Date: 2020-07-24 Impact factor: 66.675

4. Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected]

Authors: Kazuhito Izukuri; Kenji Suzuki; Nobuyuki Yajima; Shigeyuki Ozawa; Shin Ito; Eiro Kubota; Ryu-Ichiro Hata
Journal: Transgenic Res Date: 2010-03-24 Impact factor: 2.788

5. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors: Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal: Infect Immun Date: 2005-07 Impact factor: 3.441

6. Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbeta.

Authors: Bradley Yates; Craig Zetterberg; Vaishali Rajeev; Michael Reiss; Susan R Rittling
Journal: Exp Cell Res Date: 2007-08-01 Impact factor: 3.905

7. Imbalanced expression of Tif1γ inhibits pancreatic ductal epithelial cell growth.

Authors: Martin Ligr; Xinyu Wu; Garrett Daniels; David Zhang; Huamin Wang; Cristina Hajdu; Jinhua Wang; Ruimin Pan; Zhiheng Pei; Lanjing Zhang; Marcovalerio Melis; Matthew R Pincus; John K Saunders; Peng Lee; Ruliang Xu
Journal: Am J Cancer Res Date: 2014-05-26 Impact factor: 6.166

Review 8. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors: C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal: J Clin Pathol Date: 2006-08 Impact factor: 3.411

Review 9. Potential approaches to reverse or repair renal fibrosis.

Authors: Desiree Tampe; Michael Zeisberg
Journal: Nat Rev Nephrol Date: 2014-02-11 Impact factor: 28.314

Review 10. Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors: Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal: PM R Date: 2009-08 Impact factor: 2.298